Latest News

Two optical treatment modalities can slow pediatric myopia progression without the need for pharmacologic intervention, ie, spectacle lenses incorporating highly aspherical lenslets (HAL) and orthokeratology (ortho-k) contact lenses. Both treatments are based on the same underlying theory that peripheral retinal defocus is a growth signal for axial elongation‚ but the treatments focus on different structures of the visual system, one through a manufactured spectacle lens surface (HAL) and the other through temporary corneal reshaping (ortho-k).

The agency assigned a PDUFA target action date of April 30, 2027.

Japan designated gildeuretinol an orphan drug for Stargardt disease as the oral therapy enters phase 3 evaluation in the NORTHSTAR trial.

A retrospective study of nearly 1,000 patients found epithelial resolution with serial decellularized basement membrane graft use in subclinical to Stage 1 disease.

Bausch + Lomb advances dual-action dry eye drop to phase 3 and reports positive phase 1b data for TRPV1 antagonist BL1332

Angela Y. Zhu, MD, of Bascom Palmer Eye Institute, explains how to distinguish eye allergy from vision-threatening VKC and AKC in children and when steroid-sparing therapy and referral are warranted.

The over-the-counter lens is the first FDA-recognized device in its class, targeting light sensitivity in patients with episodic migraine aged 12 and older.

Large cohort links long-term tadalafil for urinary symptoms to modestly higher open-angle glaucoma risk.

Kodiak fully enrolled the first pivotal cohort of its phase 3 PEAK trial testing KSI-101 for inflammatory macular edema, with topline data expected December 2026.

A preclinical study of the effects of aflibercept (Eylea, Regeneron Pharmaceuticals) and faricimab (Vabysmo-svoa, Genentech) showed that the two treatments were equal in their ability to maintain or restore the retinal endothelial barrier function and resultant visual integrity. Investigators attributed this result mainly to inhibiting vascular endothelial growth factor A165 from binding to its receptor.

Matias Iglicki, MD, PhD, on patient selection, technical pitfalls and why symmetry decides outcomes in flanged vs sutured fixation

Noah G. Banoub discusses a study finding MacTel2 misdiagnosed in 25.5% of cases, common mimics, misleading imaging, and Encelto's approval.

Topical chloroprocaine hydrochloride ophthalmic gel 3% (IHEEZO, Harrow) resulted in less pain f following intravitreal injections in patients undergoing same-day bilateral intravitreal injections.